Biophytis S.A. (ALBPS.PA)

0.0942 €

+0.00 (+1.29%)
Rating:
Recommendation:
-
Symbol ALBPS.PA
Price 0.0942 €
Beta 1.537
Volume Avg. 1.30M
Market Cap 15.936M
Shares () -
52 Week Range 0.076-0.945
1y Target Est -
DCF Unlevered ALBPS.PA DCF ->
DCF Levered ALBPS.PA LDCF ->
ROE -447.71% Strong Sell
ROA -43.81% Strong Sell
Operating Margin -
Debt / Equity 532.63% Strong Buy
P/E -
P/B 0.22 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Stanislas Veillet
Healthcare
Biotechnology
Paris

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.